The FDA just put a pause on a cutting-edge gene editing trial that hadn't started yet - and the company's stock is dropping

Shutterstock/vchal

• The FDA just put a hold on one of the first trials to test the CRISPR gene-editing technology in humans. The trial hadn't begun yet.
• The trial, run by CRISPR Therapeutics and Vertex Pharmaceuticals, plans to look at how the gene-editing technology works to treat patients with sickle cell disease. The trial has been put on hold "pending the resolution of certain questions that will be provided by the FDA."
• CRISPR's stock fell as much as 19% after hours on Wednesday, while Vertex was largely unchanged after-hours.

Markets Insider

Visit Markets Insider for constantly updated market quotes for individual stocks, ETFs, indices, commodities and currencies traded around the world. Go Now!